Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.
暂无分享，去创建一个
L. Trippa | A. Bardia | N. Tung | E. Mittendorf | L. Ellisen | L. Spring | A. Comander | S. Isakoff | B. Moy | T. Mulvey | S. Tolaney | A. Garrido-Castro | F. Lynce | G. Fell | N. Desai | A. Rosenstock | P.K. Ryan | S. McLaughlin | Laura M. Spring